June 10, 2021

Allysta Pharmaceuticals, Inc. Announces Start of Phase 1 Clinical Trial of ALY688-SR, a Novel First-in-Class Peptide that Targets Adiponectin Signaling

​

December 15, 2020

Allysta Pharmaceuticals, Inc. Announces Positive Preclinical Data in a NASH Model Demonstrating its Adiponectin Analogue ALY688 Reduces Liver Fat, Inflammation, and Fibrosis

​

December 1, 2020

Allysta Pharmaceuticals, Inc. Announces Positive Results from its Phase 1/2a Clinical Trial of ALY688 Ophthalmic Solution in Dry Eye Disease

​

January 8, 2020

Allysta Pharmaceuticals, Inc. Doses First Patient with ALY688 Ophthalmic Solution in Phase 1/2a Dry Eye Study

​

December 18, 2019

Allysta Pharmaceuticals, Inc. Raises Additional $5 Million in Series A Financing to Advance Novel Therapeutic for NASH

April 25, 2019

Allysta Pharmaceuticals, Inc. to Present at OIS@ASCRS

​

April 22, 2019

Allysta Pharmaceuticals, Inc. to Present New Results on ALY688 at the Annual Meeting of ARVO

April 16, 2019

Allysta Pharmaceuticals, Inc. Raises $15 Million in

Series A Financing to Advance Novel Therapeutic for Dry Eye Disease 

​

April 4, 2018

Allysta Pharmaceuticals, Inc. Doses First Patient in Phase 2A Study in Glaucoma

​

May 13, 2017

Data on Allysta Pharmaceuticals’ Lead Compound, ADP355, Presented at the Annual Meeting of ARVO in Baltimore MD

Poster presented by Prof KC Yoon, Chairman, Dept Ophthalmology, Chonnam University, Korea

​

February 22, 2017

Allysta Pharmaceuticals, Inc. to present at the QB3 – 2017 Life Science Pitch Summit

​

February 22, 2017

Allysta Pharmaceuticals, Inc. to present at the National Investment Banking Association Conference

​

December 12, 2016

Allysta Pharmaceuticals, Inc. to present at the Ninth Annual Biotech Showcase Conference in San Francisco

​